Cevostamab is a bispecific antibody that targets FcRH5, a protein expressed in B-cell malignancies and multiple myeloma cells. It is specifically located on the 1q chromosome.
This Phase 2 study is for relapsed/refractory multiple myeloma patients who received a CAR T-cell infusion.
The purpose of this study is to assess the impact of cevostamab consolidation after a BCMA-targeted CAR T-cell therapy on the rate of minimal residual disease (MRD) negative complete remission (CR) at 12 months.
This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
Patients who have received BCMA-directed therapy are qualified to join.
